Single User License
INR 170425
Site License
INR 340850
Corporate User License
INR 511275

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Vitreomacular Adhesion VMA Global Clinical Trials Review, H2

Vitreomacular Adhesion VMA Global Clinical Trials Review, H2


  Request for Sample Report

Executive Summary

Vitreomacular Adhesion (VMA) Global Clinical Trials Review, H2, 2015

GlobalData's clinical trial report, "Vitreomacular Adhesion (VMA) Global Clinical Trials Review, H2, 2015" provides an overview of Vitreomacular Adhesion (VMA) clinical trials scenario. This report provides top line data relating to the clinical trials on Vitreomacular Adhesion (VMA). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Vitreomacular Adhesion (VMA) 6

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Clinical Trials by G7 Countries: Proportion of Vitreomacular Adhesion (VMA) to Ophthalmology Clinical Trials 13

Clinical Trials by Phase in G7 Countries 14

Clinical Trials in G7 Countries by Trial Status 15

Clinical Trials by Phase 16

In Progress Trials by Phase 17

Clinical Trials by Trial Status 18

Clinical Trials by End Point Status 19

Subjects Recruited Over a Period of Time 20

Clinical Trials by Sponsor Type 21

Prominent Sponsors 22

Top Companies Participating in Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials 23

Prominent Drugs 24

Latest Clinical Trials News on Vitreomacular Adhesion (VMA) 25

Jul 13, 2015: Allegro Ophthalmics Announces Positive Topline Results From Phase 2 Trial Evaluating Luminate In Patients With Vitreomacular Traction Or Vitreomacular Adhesion 25

Jun 17, 2015: Vitreomacular adhesion patients report improved vision with non-surgical treatment in USC Eye Institute-led clinical studies 25

Clinical Trial Profiles 27

Clinical Trial Overview of Top Companies 27

ThromboGenics NV 27

Clinical Trial Overview of ThromboGenics NV 27

Allegro Ophthalmics, LLC 28

Clinical Trial Overview of Allegro Ophthalmics, LLC 28

Ophthalmic Consultants of Boston 29

Clinical Trial Overview of Ophthalmic Consultants of Boston 29

Novartis AG 30

Clinical Trial Overview of Novartis AG 30

Kato Pharmaceuticals, Inc. 31

Clinical Trial Overview of Kato Pharmaceuticals, Inc. 31

Alcon, Inc. 32

Clinical Trial Overview of Alcon, Inc. 32

Clinical Trial Overview of Top Institutes / Government 33

Dong Rae Bong Seng Hospital 33

Clinical Trial Overview of Dong Rae Bong Seng Hospital 33

NTT East Tohoku Hospital 34

Clinical Trial Overview of NTT East Tohoku Hospital 34

University of California, Los Angeles 35

Clinical Trial Overview of University of California, Los Angeles 35

Five Key Clinical Profiles 36

Appendix 79

Abbreviations 79

Definitions 79

Research Methodology 80

Secondary Research 80

About GlobalData 81

Contact Us 81

Disclaimer 81

Source 82

List of Figures

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials by Region (%), 2015* 7

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11

Proportion of Vitreomacular Adhesion (VMA) to Ophthalmology Clinical Trials, G7 Countries (%), 2015* 13

Vitreomacular Adhesion (VMA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 14

Vitreomacular Adhesion (VMA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 15

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 16

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 17

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 18

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 20

Vitreomacular Adhesion (VMA) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 21

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 22

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 23

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 24

GlobalData Methodology 80

List of Tables

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials by Region, 2015* 7

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12

Proportion of Vitreomacular Adhesion (VMA) to Ophthalmology Clinical Trials, G7 Countries (%), 2015* 13

Vitreomacular Adhesion (VMA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 14

Vitreomacular Adhesion (VMA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 15

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials by Phase, 2015* 16

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 17

Vitreomacular Adhesion (VMA) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 18

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 19

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 20

Vitreomacular Adhesion (VMA) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 21

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 22

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 23

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 24

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by ThromboGenics NV, 2015* 27

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Allegro Ophthalmics, LLC, 2015* 28

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ophthalmic Consultants of Boston, 2015* 29

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 30

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Kato Pharmaceuticals, Inc., 2015* 31

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Alcon, Inc., 2015* 32

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Dong Rae Bong Seng Hospital , 2015* 33

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by NTT East Tohoku Hospital, 2015* 34

Vitreomacular Adhesion (VMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Los Angeles, 2015* 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ThromboGenics NV

Allegro Ophthalmics, LLC

Ophthalmic Consultants of Boston

Novartis AG

Kato Pharmaceuticals, Inc.

Alcon, Inc.

Vitreomacular Adhesion (VMA) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Vitreomacular Adhesion (VMA), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com